02/21
Headlines

BIND Therapeutics

Stocks in Focus : BIND Therapeutics (NASDAQ:BIND), Bristol-Myers Squibb (NYSE:BMY), TC PipeLines (NYSE:TCP), Entergy Corporation (NYSE:ETR), Rigel Pharmaceuticals (NASDAQ:RIGL)

Jayne Crisman03 mins

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced the appointments of Eric K. Rowinsky, M.D. and Amy W. Schulman to the company’s board of directors. Together the significant insights and expertise of these two industry leaders will help to guide BIND’s management team in…

Read More

Stocks in Focus: BIND Therapeutics, Inc. (NASDAQ:BIND), Bristol-Myers Squibb Company (NYSE:BMY), TC PipeLines, LP (NYSE:TCP), Entergy Corporation (NYSE:ETR), Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

Kristen Barton03 mins

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced the appointments of Eric K. Rowinsky, M.D. and Amy W. Schulman to the company’s board of directors. Together the significant insights and expertise of these two industry leaders will help to guide BIND’s management team in…

Read More

Biotech Volatile Stocks: BIND Therapeutics (NASDAQ:BIND), Oncomed Pharmaceuticals Inc (NASDAQ:OMED), Advaxis (NASDAQ:ADXS), Enzon Pharmaceuticals Inc (NASDAQ:ENZN)

Chris Lewis02 mins

BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced it will report fourth quarter and year ended December 31, 2013 financial results on Tuesday, March 25, 2014. BIND Therapeutics Inc (NASDAQ:BIND) stock performance was 7.75% in last session and finished the day at $12.93. Traded volume…

Read More